SCHEMBL10132973

SCHEMBL10132973

CN1CCN(CCOc2ccc(-c3ccc(OC(=O)NCc4ccccc4)cc3)cc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LTA4H P09960 5/20 0.58
▸ NPC1 O15118 1/20 0.55
▸ RAB9A P51151 1/20 0.55
▸ TUBB4A P04350 5/20 0.54
▸ TUBB P07437 5/20 0.54
▸ TUBA3C P0DPH7 5/20 0.54
▸ TUBA1B P68363 5/20 0.54
▸ TUBA4A P68366 5/20 0.54
▸ TUBB4B P68371 5/20 0.54
▸ TUBB3 Q13509 5/20 0.54
▸ TUBB2A Q13885 5/20 0.54
▸ TUBB8 Q3ZCM7 5/20 0.54
▸ TUBA3E Q6PEY2 5/20 0.54
▸ TUBA1A Q71U36 5/20 0.54
▸ TUBA1C Q9BQE3 5/20 0.54
▸ TUBB6 Q9BUF5 5/20 0.54
▸ TUBB2B Q9BVA1 5/20 0.54
▸ TUBB1 Q9H4B7 5/20 0.54
▸ ABL1 P00519 1/20 0.54
▸ LYN P07948 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10133026 0.89 TUBB4A (0.57) LTA4HNPC1RAB9ATUBB4ATUBB
SCHEMBL10132819 0.88 SRC (0.68) LTA4HNPC1RAB9ATUBB4ATUBB
SCHEMBL10132964 0.86 TUBB4A (0.63) LTA4HNPC1RAB9ATUBB4ATUBB
SCHEMBL10132968 0.85 AURKA (0.61) LTA4HNPC1RAB9ATUBB4ATUBB
SCHEMBL10132927 0.83 ABL1 (0.62) LTA4HNPC1RAB9ATUBB4ATUBB
SCHEMBL10133030 0.82 TUBB4A (0.58) LTA4HNPC1RAB9ATUBB4ATUBB
SCHEMBL11917546 0.81 TUBB4A (0.81) LTA4HNPC1RAB9ATUBB4ATUBB
SCHEMBL10132967 0.80 LTA4H (0.64) LTA4HNPC1RAB9A
SCHEMBL10132825 0.78 TUBB4A (0.71) LTA4HNPC1RAB9ATUBB4ATUBB
SCHEMBL10133046 0.78 MGLL (0.65) NPC1RAB9AFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124605-B2 Compositions and methods for modulating a kinase cascade KINEX PHARMACEUTICALS, LLC (US) 2012-02-28 — — US disclosed
US-8124605-B2 Compositions and methods for modulating a kinase cascade KINEX PHARMACEUTICALS, LLC (US) 2012-02-28 — — US disclosed
US-20090149510-A1 Compositions and methods for modulating a kinase cascade OAKTREE FUND ADMINISTRATION, LLC 2009-06-11 — — US disclosed
US-20090149510-A1 Compositions and methods for modulating a kinase cascade OAKTREE FUND ADMINISTRATION, LLC 2009-06-11 — — US disclosed
WO-2009009041-A2 COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE KINEX PHARMACEUTICALS, LLC (US) 2009-01-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149510-A1 Compositions and methods for modulating a kinase cascade MAP3K6, MAP3K4, MAP3K3 LTA4H 3326/4885NPC1 3447/4885RAB9A 2804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback